fbpx
    • Multiple Myeloma News
    • Oct 14, 2019

    Something New to Learn in Multiple Myeloma: Invariant Natural Killer T-Cells (iNKT)

image_print

A team from UCLA Life Sciences recently published exciting research with engineered natural killer T-cells that could provide long lasting immunity against cancer through the use of invariant Natural Killer T-cells (iNKT’s). iNKT’s have been labeled as the ‘special forces’ of the immune system.

Scientists have shown in the past that iNKT’s can target many types of cancer at once, whereas most immune cells can only recognize and target one specific type of cancer cell. Prior research has also shown that those folks with higher levels of iNKT-cells generally live longer than those with lower levels. The problem with being able to use iNKT’s in clinical practice is that we have too few of them. In most cases, less than 0.1 % of our blood cells are iNKT-cells.

The UCLA research team set out to … create a therapy that would permanently boost the body’s ability to naturally produce more iNKT cells.’ The team started with hematopoeitic stem cells, something that most of us multiple myeloma patients are familiar with. We (MM’ers) also know that stem cells, in a healthy environment, mature into a whole host of different of different blood and immune cells, and that includes iNKT’s.

The researchers are now credited with the discovery of how stem cells, that can be readily harvested, can be genetically engineeredso that they were programmed to develop into iNKT cells’. The resultant cells are called HSC-iNKT’s (Hematopoietic Stem Cell-iNKT’s). ‘These HSC-iNKT cells closely resembled endogenous human iNKT cells, could deploy multiple mechanisms to attack tumor cells, and effectively suppressed tumor growth in vivo in multiple human tumor xenograft mouse models.’

The team now had adequate amounts of HSC-iNKT’s to test in a variety of ‘humanized mouse’ models ‘… with both human bone marrow and human cancers — either multiple myeloma (a blood cancer) or melanoma (a solid tumor cancer) — and studied what happened to the mice’s immune systems, the cancers and the HSC-iNKT cells after they had integrated into the bone marrow.’ [emphasis added]

The conclusions from this early research are exciting :

  • ‘… the stem cells differentiated normally into iNKT cells and continued to produce iNKT cells for the rest of the animals’ lives…’;
  • ‘One advantage of this approach is that it’s a one-time cell therapy that can provide patients with a lifelong supply of iNKT cells’.
  • ‘While mice without the engineered stem cell transplants had nearly undetectable levels of iNKT cells, in those that received engineered stem cell transplants, iNKT cells made up as much as 60% of the immune systems’ total T cell count. Plus, researchers found they could control those numbers by how they engineered the original hematopoietic stem cells.’
  • ‘the team found that in both multiple myeloma and melanoma, HSC-iNKT cells effectively suppressed tumor growth.’ [emphasis added]
  • ‘ … hematopoetic stem cells collected either from a person with cancer or a compatible donor could be used to engineer HSC-iNKT cells in the lab.’

More work is needed to build on the discovery and to advance this research program into human trials. Several issues will need to be resolved.  Will the increase in the number of iNKT-cells in humans cause longer term side effects ? How many HSC-iNKT’s will need to be infused into a patient for adequate tumor load suppression/elimination? Time will tell how this story will play out. I am reminded though that, six years ago when I started my own journey, CAR-T was very much in its infancy and now we already have two FDA approved products on the market and +100 CAR-T programs in clinical trials. FDA has proven over the past few years that they are willing to rapidly advance projects with urgent patient need and/or projects that offer breakthrough cure potential. Keep those fingers crossed.

For those interested in learning more there is also this added reference issued by UCLA.

The first reference provided at the start of this post provides a nice graphic that summarizes the process (see below).

 

 

 

 

 

 

 

 

About Author

Paul Kleutghen

I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and a grandson who is the ‘light of my life’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs and, very specifically, CAR-T therapies, with recent contributions posted by Health affairs, the Institute for Clinical and Economic Review and the Centers for Medicare and Medicaid Services.

One Comment

  1. Mike Palumbo Jr October 15, 2019 at 4:05 pm

    Very compelling, the continued production of these cells is very intriguing…
    Almost sounds like a possible cure or at least long term management for myeloma…
    Human trials will tell…
    Godspeed….

Leave A Comment

Please enter the correct captcha code to verify that you are human.

MYELOMA CROWD RESEARCH INITIATIVE
$167301 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: